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Abstract 
Background: To examine for a possible relationship between osteoarthritis and cardiovascular 
disease (CVD).  
Design: A systematic review and meta-analysis 
Methods: Published and unpublished literature from: MEDLINE, EMBASE, CINAHL, the 
Cochrane Library, OpenGrey and clinical trial registers. Search to 22nd November 2014. Cohort, 
case-control, randomised and non-randomised controlled trial papers reporting the prevalence 
of CVD in osteoarthritis were included.  
Results: Fifteen studies with 32,278,744 individuals were eligible. Pooled prevalence for overall 
CVD pathology in people with osteoarthritis was 38.4% (95% Confidence interval (CI): 37.2% to 
39.6%). Individuals with osteoarthritis were almost three times as likely to have heart failure 
(Relative Risk (RR): 2.80; 95% CI: 2.25 to 3.49) or ischaemic heart disease (RR: 1.78; 95% CI: 
1.18 to 2.69) compared to matched non-osteoarthritis cohorts. No significant difference was 
detected between the two groups for the risk of experiencing myocardial infarction or stroke. 
There was a three-fold decrease in the risk of experiencing a transient ischaemic attack in the 
osteoarthritis cohort compared to the non-osteoarthritis group.   
Conclusions: Prevalence of CVD in patients with OA is significant. There was an observed 
increased risk of incident heart failure and ischaemic heart disease in people with OA compared 
to matched controls. However the relationship between OA and CVD is not straight-forward and 
there is a need to better understand the potential common pathways linking pathophysiological 
mechanisms. 
Work Count (Abstract): 221 
Keywords: osteoarthritis; cardiovascular disease; cerebrovascular disease; myocardial infarct; 
hypertension 
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Introduction 
Osteoarthritis (OA) is a common musculoskeletal disorder that presents with joint pain and 
stiffness, fatigue and consequently reduces people’s function and quality of life.1,2 Osteoarthritis 
of the knee has a prevalence of over 250 million people globally.3 It is anticipated that this 
number will rise sharply in the future due to rapidly growing, ageing populations paralleled 
with the increasing prevalence of obesity. As a result, osteoarthritis is expected to impose a 
significant burden to the health economy. This will have a particular major burden on primary 
care, where it is predicted that by 2032 an additional 26,000 per one million patients aged over 
45 years will consult their general practitioner with osteoarthritis compared to 2012.4 
 
Cardiovascular diseases (CVD) such as stroke and myocardial infarction (MI) are a leading cause 
of mortality, accounting for 17.3 million people globally, and expected to rise to 23.3 million by 
2030.5 Previous studies have reported an association between chronic musculoskeletal diseases 
and CVD such as MI, cerebrovascular disease, peripheral vascular disease and heart failure.6-8 
Most notably, such an association has been reported for rheumatoid arthritis,9 fibromyalgia10 
and low back pain.11 Traditional risk factors for CVD, including age, male sex, obesity, family 
history, smoking and diabetes mellitus,12 are also associated with the development and 
progression of symptomatic osteoarthritis,13,14 potentially highlighting shared 
pathophysiological processes/pathways in their development.  
 
It has been hypothesised that genetic, metabolic and neuroendocrine factors may also increase 
the prevalence of osteoarthritis.15 Principally this may be associated with excessive 
proinflammatory cytokine production associated with osteoarthritis and with atherogenic 
effects associated with hypertension. The former has also been associated with the 
microvasculature of subchondral bone, which plays a role in the pathogenesis of 
osteoarthritis.16,17 Many of these inflammatory processes and cytokines contribute to vascular 
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inflammation and atherosclerosis development that underlie many CVD such as hypertension, 
MI, heart failure and cerebrovascular disease.18 The interrelationship between osteoarthritis 
and CVD, their shared risk factors and underlying pathophysiological mechanisms are complex 
and it is unknown whether patients with osteoarthritis are at increased risk of CVD, 
independent of their risk factor profile and age.  
 
Therefore the purpose of this study is to systematically examine the literature to determine 
whether there is an association between osteoarthritis and CVD, such as cardiac failure, MI, 
stroke and peripheral vascular disease, and to quantify such associations using meta-analysis 
techniques where feasible. 
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Materials and Methods 
The systematic review was conducted in accordance with the PRISMA guidelines19 and followed 
a published predetermined protocol (PROSPERO CRD 42014007021). 
 
Data Sources and Searches 
 
Two reviewers (AJH and BS) independently conducted the searches of electronic databases 
including: MEDLINE, EMBASE, CINAHL, AMED (via Ovid), BNI, PsycINFO, Cochrane Library, 
PubMed and the PEDro database from their inception to 22nd November 2014. An example of 
the MEDLINE search strategy is presented in Supplementary Table 1. The search terms were 
modified for individual databases. 
 
Unpublished and trial registry databases were screened and included: OpenGrey, the WHO 
International Clinical Trials Registry Platform, Current Controlled Trials and the UK National 
Research Register Archive from their inception to 22nd November 2014. All references lists of all 
potentially eligible studies and review papers were searched to identify any studies initially 
omitted. 
 
Study Selection 
 
Studies were included if they were conducted in humans and were case-controlled cohort or 
cross-sectional studies investigating the association between osteoarthritis and CVD, and which 
recorded osteoarthritis according to recognised criteria (e.g. American College of Rheumatology 
definitions20), self-report or self-reported physician-diagnosed osteoarthritis. We considered 
participants with osteoarthritis affecting any joint. Studies which recruited people with non-
osteoarthritis diagnoses such as rheumatoid arthritis, fibromyalgia or chronic pain were 
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excluded, unless data for osteoarthritis were presented in an extractable form. Studies were 
included if there was a report of a CVD event (e.g. MI, ischaemic heart disease (defined as 
coronary artery disease or stable angina), stroke, peripheral vascular disease, atherosclerosis, 
chronic cardiac failure). Cardiovascular disease was defined as a composite end-point of a 
diagnosis of stroke, MI, heart failure, coronary heart disease, peripheral vascular disease or 
atherosclerosis. We were interested in any CVD events and not just first-time cardiovascular 
events. We also included the baseline data of any randomised controlled trials reporting the 
relationship between CVD and osteoarthritis. Single-case study papers were excluded. No 
restrictions were placed on the age or language of publication. 
 
Based on the eligibility criteria, two reviewers (AJH and BS) independently reviewed the titles 
and abstracts from potentially relevant papers identified through the aforementioned search 
strategy. The full-text of all potentially eligible papers was reviewed before making a final 
decision on eligibility. Any disagreements in paper eligibility were resolved through a senior 
reviewer (TS). 
 
Data Extraction and Quality Assessment 
Data were extracted onto a data extraction form by one reviewer (AJH) and verified by two 
further reviewers (BS and TS). Data extracted included: country in which the study was 
conducted; joint affected by osteoarthritis; number of cases and controls; gender of 
participants; mean age of cases and controls; reported co-morbidities; cardiovascular risk 
factors; method of assessing CVD presence or risk; prevalence of CVD in cases and controls 
(including adjustments in the model for case-control longitudinal studies); and type of CVD 
reported within cohorts. 
Each included paper was critically appraised using the Critical Appraisal Skills Programme 
(CASP) ‘Case Control’ appraisal tool.21 Each included paper was assessed for quality and bias by 
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one reviewer (AJH) and independently verified by a second reviewer (BS). Any disagreements 
in appraisal outcomes were discussed and resolved by a third reviewer (TS). 
 
Data Synthesis and Analysis 
Where clinical and statistical homogeneity was apparent, we assessed the relationship between 
osteoarthritis and CVD using meta-analysis techniques. Thus the primary analysis was to assess 
the point prevalence of any CVD events. A priori conditions were defined as including (but not 
limited to): MI, stroke, transient ischaemic attack (TIA), peripheral vascular disease, 
atherosclerosis or chronic cardiac failure in people with osteoarthritis. Secondly, we assessed 
the relative risk (RR) and 95% confidence intervals (CI) of incident of CVD (as defined above) in 
participants with osteoarthritis compared to participants with non-osteoarthritis in cohort 
studies. Where possible, data analyses were adjusted for variables such as age, gender, smoking 
habit, alcohol consumption, body mass index (BMI) as possible CVD risk factors. Study statistical 
heterogeneity was assessed using the I-squared test.  
 
Subgroup analyses were planned to assess whether there was a difference in prevalence or 
relative risk of CVD events dependent on anatomical region affected by osteoarthritis. It was not 
possible to undertake a subgroup analysis by region of osteoarthritis due to the current data 
available.  
 
Analyses were performed using STATA version 12.0 (StataCorp LP, Texas, USA) and Revman 
Version 5.1 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011). 
 
Role of Funding Sources 
No funding was received for the conduct of this systematic review. 
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Results 
Search strategy results 
A total of 1624 citations were identified from the search strategy. After reviewing the titles and 
abstracts, 15 were eligible based on our a priori eligibility criteria. A summary of the search 
results is presented in Figure 1. 
Critical appraisal 
The results of the critical appraisal are presented in Supplementary Table 2. Overall, the 
evidence-base presented was of high methodological quality. A recurrent strength across the 
evidence-base were that the exposure to osteoarthritis and outcomes of CVD appeared to be 
measured and assessed in a robust manner in all studies except Jonsson et al22 study which did 
not report how CVD status was assessed. All studies with the exception of Reid et al23 accounted 
for important confounding variables such as age, gender, co-morbidities and lifestyle risk 
factors for CVD such as smoking, alcohol consumption and BMI in their analyses. The principle 
limitation with regards to quality of studies was an inadequate follow-up duration as four out of 
15 studies were cross-sectional.24-27 
Characteristics of included studies 
A summary of the included studies characteristics is presented in Supplementary Table 3. This 
included six cross-sectional study.23,28-32 four prospective longitudinal cohort studies,22,24,25,33 
three case-control studies17,26,34,35 and one retrospective cohort study.27 A total of 32,278,744 
participants from the 15 studies (11,027,587 males; 20,763,074 females) were included. A total 
of 254,440 events of CVD within cases and 417,779 events in controls were reported from the 
10 studies which presented this data. The mean age across the studies for osteoarthritis cases 
ranged from 58.2 years to 68.5 years, whilst the control groups were marginally younger with a 
mean ranging from 51.029 to 67.2 years.32 The assessment of CVD was performed by various 
11 
 
approaches including medical history and examination, laboratory and clinical assessments and 
self-reporting (Supplementary Table 3). The documented CVD risk factors are presented in 
Supplementary Table 4. 
Primary analysis: Prevalence of CVD 
The findings on prevalence of CVD for people with osteoarthritis are presented in Table 1. 
There was a high prevalence when CVD was considered for all CVD pathologies with a pooled 
prevalence of 38.4% (95% CI: 37.2% to 39.6%) in osteoarthritis cases compared to controls 
which was 9% (95% CI: 8% to 9%; p=0.01). However, the prevalence for specific CVDs was low, 
ranging from 9% (95% CI: 8% to 10%) for ischaemic heart disease in the osteoarthritis 
compared to 4% (95% CI: 4% to 4%) in the control group (p=0.006) and 2% (2% to 3%) in the 
osteoarthritis participants for TIAs compared to 6% (95% CI: 6% to 6%) in the control group 
(p<0.001).  However, as Table 1 indicates, the prevalence for CVD as a whole was significantly 
greater in the osteoarthritis cohort (prevalence: 38% versus 9%) compared to the controls 
(p=0.01). 
Secondary analysis: Comparative relative risk of CVD in osteoarthritis and non-osteoarthritis 
cohorts? 
A summary of the comparison between the relative risk of CVD between osteoarthritis and non- 
osteoarthritis cohorts is presented in Figure 2. There were statistically significant increased 
relative risks (over two fold) of heart failure and ischaemic heart disease in participants with 
osteoarthritis compared to non- osteoarthritis participants (Table 1). The relative risk and 
corresponding 95% CI of these conditions were 2.80 (95% CI: 2.25 to 3.49) and 1.78 (95% CI: 
1.18 to 2.69) respectively. Interestingly, the risk of TIA was lower in the osteoarthritis cohort 
compared to the non-osteoarthritis cohort; people with osteoarthritis had a three-fold 
decreased risk of experiencing a TIA compared to the non-osteoarthritis group (RR: 0.33; 95% 
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CI: 0.27 to 0.41). There was no statistically significant difference in risks of experiencing a MI or 
stroke between the osteoarthritis and non-osteoarthritis cohorts (p≥0.09; Table 2).  
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Discussion 
To our knowledge, this is the first and the largest systematic review and meta-analysis involving 
data from over 32 million participants to investigate the relationship between osteoarthritis 
and CVD both in terms of prevalence and risk of subsequent CVD.  We established that people 
with osteoarthritis have significantly higher prevalence of overall CVD.  Moreover, we found 
that individuals with osteoarthritis were over twice as likely to experience heart failure or 
ischaemic heart disease compared to people without osteoarthritis. Given the ageing global 
demographic and the fact that both conditions are prevalent in older age, it is more important 
than ever to consider these two groups of pathologies together. 
Our findings of high prevalent levels of CVD among people with osteoarthritis are concerning 
for several reasons.  First, CVD is a leading cause of premature mortality, with the World Health 
Organisation stating that it accounts for approximately half of all premature deaths across 
Europe.5 In addition, osteoarthritis remains one of the most burdensome chronic 
musculoskeletal conditions affecting large numbers of people and is a leading cause of years 
lived with disability.36  
Previous authors have suggested a potential synergistic effect between certain co-morbidities in 
the elderly.37-39 Such hypotheses have included damage to blood vessels supplying the 
subchondral bone may contribute to the pathophysiology of osteoarthritis. Such could occur 
from hypertension which can result in vascular damage. Alternatively atherosclerosis and 
osteoarthritis are both being inflammatory processes involving inflammatory mediators which 
has demonstrated histological evidence of inflammation in vessel walls, joints and synovium.18 
However it remains unclear as to whether there is an interaction between osteoarthritis and 
CVD. There is also uncertainty as to how these may change and associate over time, and 
whether an ageing sample present with different co-occurring diseases over time. Further 
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longitudinal cohort studies will better inform how this occurs and whether there is a causal 
relationship between pathologies over a sufficient study period.  
Interestingly, there were no statistically significant differences in risk of developing stroke and 
experiencing a MI, and even a protective effect with reduced risk of TIA observed in 
osteoarthritis cohorts. We observed high I2 values indicating an extremely statistically 
heterogeneous nature of included studies for stroke and MI outcomes and this could potentially 
explain the null finding. This apparent discrepancy may arise with healthy survival bias as 
population characteristics (Supplementary Table 3) and CVD risk factors (Supplementary 
Table 4) from the included studies would support this hypothesis. This may therefore occur 
through the timing of these CVD events which occur later in life compared to hypertension and 
ischaemic heart disease, key risk factors for stroke and MI, respectively, which occur earlier in 
life. Treating these risk factors (hypertension and ischaemic heart disease) earlier in the life-
course in people with osteoarthritis may attenuate their later CVD risk significantly in some of 
the cohorts included in the meta-analysis. One other plausible explanation which could account 
for the reduced risk of TIA is healthy survival bias, i.e. people with high CVD risk factors may 
had died prematurely and hence the studies which examined the risk of stroke, TIA and MI may 
consist of relatively healthier surviving osteoarthritis participants, whilst controls within these 
studies might have unknown CVD risk factors or pre-clinical stage which were not treated.     
Our results have important clinical implications and considerations.  It is important to note that 
an increased prevalence of CVD in osteoarthritis may impact on management options and 
outcomes for patients. Patients with comorbid diseases are less likely to be suitable candidates 
for surgical intervention, limiting the options available to treat and prevent progression of 
osteoarthritis. Furthermore those patients who do undergo surgery will be at an increased risk 
of peri- and post-operative complications e.g. anaesthetic complications, venous 
thromboembolism, MI and infection.  Another important factor to consider in the association 
between osteoarthritis and CVD is the use of non-steroidal anti-inflammatories (NSAIDs), which 
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are known to result in increased risk of heart failure, hypercholesterolaemia, hypertension, 
heart disease and stroke.40 This may precipitate CVD in patients treated for osteoarthritis, and 
may limit management options in patients with osteoarthritis who already have known CVD. 
Outside of this, the cornerstone of the prevention and management of CVD is the promotion of 
physical activity.41 People with osteoarthritis experience a range of barriers to engaging in 
physical activity, including higher levels of pain, increased BMI and lower levels of function.42 
Physiotherapists and other qualified professionals should seek to address and overcome these 
barriers to help the individual engage in physical activity.  This may be particularly important 
given that physical activity demonstrates comparable effectiveness to pharmacological 
interventions in preventing cardiovascular disease outcomes,43 and it is effective in reducing 
pain and disability in this group.44  Therefore physical activity should be given a higher priority 
in the management of osteoarthritis throughout the duration of the condition to not only 
manage osteoarthritis symptoms but also to maintain cardiovascular health.   
It was not possible, from this dataset, to determine a causal relationship between osteoarthritis 
and CVD pathologies as the compilation of evidence in this systematic review and meta-analysis 
were derived mainly from observational studies. This should be considered when interpreting 
the findings from this analysis.  Moreover, it was not possible to conduct moderation analyses to 
consider factors that may account for this increased risk.  Thus, the reasons why people with 
osteoarthritis appear more likely to experience high and increased levels of CVD is unclear but 
warrants attention.   
The typical age of assessment varied e.g. ischaemic heart disease are more likely to occur in 
individuals over than 50 years of age whilst stroke and TIA are more prevalent after 65 years. 
Both may introduce selection bias by virtue of timing of event and hence people may receive 
preventative measures, or by selection bias due to people with less significant CVD events 
surviving and hence having a reduced risk of events (e.g. stroke) later events in life. It may also 
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be important to consider that this meta-analysis does not provide insight relating to the 
management of patients’ cardiovascular risk factors or incident cardiovascular events and 
whether there is significant heterogeneity amongst patients with and without osteoarthritis. It 
is unclear whether patients with significant osteoarthritis receive similar access to evidence-
based therapies and invasive interventions when diagnosed with CVD such as MI or stroke 
compared to patients without osteoarthritis, or whether patients with osteoarthritis are at a 
disadvantage for the provision of such therapy because of perceived frailty, risk or poor efficacy 
of therapies in such patients groups. 
Our analysis suggests patients with osteoarthritis have a significantly higher prevalence of CVD 
than those without osteoarthritis and are twice as likely to develop ischaemic heart disease and 
heart failure. The optimal screening strategy for such patients with osteoarthritis is unclear 
with no clear recommendations in national society guidelines specifically for this patient group. 
Given the adverse risk factor profile in people with osteoarthritis that we report, we would 
advocate that future cardiovascular risk in these high-risk patients should be assessed formally 
using established cardiovascular risk scores such as SCORE, currently recommended for risk 
assessment in the asymptomatic adult without evidence of CVD by the European Society of 
Cardiology guidelines on CVD prevention (2012).45 In people with osteoarthritis identified as 
low risk, risk assessment should be repeated at 5-year intervals in line with current 
recommendations if there are no significant changes in the major risk factor profile.45 
Aggressive risk factor management for those people with osteoarthritis found to be a high risk 
from future cardiovascular events should be advocated in addition to lifestyle changes. Such 
approaches in risk factor management have been shown to be effective, with up to 50% 
decreases in coronary heart disease mortality brought on by lifestyle changes and risk factors 
modifications.46  
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Study Limitations 
Although this study is the first of its kind, our study has some limitations which are worth 
highlighting. First, four studies were cross-sectional and therefore directionality of the variables 
cannot be deduced with certainty.  Second, the longitudinal studies had relatively short follow-
up periods. Third, a large proportion of studies relied upon the medical and/or prescription 
records to ascertain CVD status. Studies relying upon this method are likely to be an under-
estimate since some cardiovascular risk factors. Fourth, due to nature of the studies, we were 
unable to determine whether patients with osteoarthritis have worse CVD outcomes because of: 
a more adverse CVD risk factor profile; the use of anti-platelet, NSAID, statin or ACE-inhibitor 
medications which are known to influence CVD event rates; or more adverse outcomes 
independent of their risk profile which may point towards a shared pathophysiological 
mechanism. Finally, it was not possible to analyse the association between risk score and 
cardiovascular events occurrence, or to evacuate if people with a high risk (metabolic syndrome 
or diabetes for example) and osteoarthritis had a higher risk of CVD events compared with 
people at low risk. This data was not available from the current evidence-base, and may be best 
analysed through Individual Patient Data analyses. If such comparisons are possible with future 
data, we could better understand if osteoarthritis is associated with an increased risk with or 
without increasing risk factors. 
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Figure 1: PRISMA Flow-Chart 
 
 
Records identified through database 
searching (N = 1619) 
Additional records identified through 
other sources (N= 5) 
Records after duplicates removed  
(N = 1234) 
Records screened (N = 719) Records excluded at abstract 
level (N = 664) 
Full-text articles assessed for eligibility (N =55) Full-text articles excluded 
(N=40), with reasons:  
N=18 Not OA population 
N=14 no relevant CVD data 
N=8 investigating prevalence of 
OA in sample with CVD 
Studies included in narrative synthesis (N =15) 
Studies included in meta-analysis (N =15) 
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 Figure 2: Forest-plot presenting the relative risk of different CVD for OA and non-OA cohorts. 
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 Table 1: Point prevalence of CVD in people with osteoarthritis 
 
CVD  Analysed 
Studies 
Osteoarthritis Cohort Control Cohort P-value 
Point Prevalence 
(95% CI) 
Cohort 
Proportions 
Point Prevalence 
(95% CI) 
Cohort 
Proportions 
Overall CVD [29,30,33,34] 0.38 (0.37 to 0.40) 2367/6165 0.09 (0.08 to 0.09) 859/9874 0.01 
Stroke [29,30,33] 0.04 (0.04 to 0.05) 281/6640 0.09 (0.09 to 0.09) 15139/168319 1.00 
MI [29,30] 0.04 (0.03 to 0.04) 215/5914 0.07 (0.07 to 0.07) 12118/168313 0.78 
HF [30,33] 0.05 (0.04 to 0.06) 125/2600 0.02 (0.02 to 0.02) 212/10536 <0.001 
IHD [30,33] 0.09 (0.08 to 0.10) 226/2600 0.04 (0.04 to 0.04) 406/10496 0.006 
TIA [29] 0.02 (0.02 to 0.03) 81/4040 0.06 (0.06 to 0.06) 9506/158439 <0.001 
 
CI – confidence intervals; CVD – cardiovascular disease; IHD – ischemic heart disease; HF – heart failure;t MI – myocardial infarct; TIA – transient 
ischemic attack.
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Table 2: Relative risk of CVD occurring compared to non-osteoarthritis control cohorts 
CVD Analysed 
Studies 
Relative risk of occurring 
compared to non-OA 
control (95% CI)* 
P-value  Cohort  
 Exposed 
(positive/cohort) 
Control  
(positive/cohort) 
Overall CVD [29,30,33,34] 1.69 (1.13 to 2.53) 0.01 2422/6891 57003/169467 
Stroke [29,30,33] 1.00 (0.13 to 7.87) 1.00 281/6640 14532/168935 
MI [29,30] 0.69 (0.05 to 8.98) 0.78 215/5914 11456/168313 
HF [30,33] 2.80 (2.25 to 3.49) <0.001 125/2600 212/10496 
IHD [30,33] 1.78 (1.18 to 2.69) 0.006 399/3085 487/10867 
TIA [29] 0.33 (0.27 to 0.41) <0.001 81/4040 9506/158439 
 
*data based on adjusted analyses. 
 
CI – confidence intervals; CVD – cardiovascular disease; IHD – ischemic heart disease; HF – heart failure; MI – myocardial infarct; TIA – transient 
ischemic attack. 
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Supplementary Table 1: Search terms adopted for the MEDLINE search strategy 
 
 1. Osteoarthritis 
2. Arthriti$ 
3. Degenerate$ 
4. OR/1-3 
5. Cardiovascular 
6. Stroke 
7. Cerebrovascular 
8. Peripheral vascular  
9. Myocardial infarction 
10. Coronary heart disease 
11. Ischaemic heart disease 
12. Atherosclero$ 
13. Coronary revascularis$ 
14. Chronic cardiac failure 
15. Dementia$ 
16. Vascular dementia  
17. Hypertension 
18. Blood pressure 
19. Atrial fibrillation 
20. Angina  
21. Metabolic syndrome 
22. Mortality 
23. Cardiovascular mortality 
24. Death 
25. OR/5-25 
26. AND/4,25 
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Supplementary Table 2: Summary of critical appraisal assessment 
Study Appraisal Criterion 
1 2 3 4 5 6 7 8 9 10 
Dahaghin [32] √ √ √ √ √ √ N/A √ √ √ 
Han [17] √ √ √ √ √ √ N/A √ √ √ 
Haugen [33] √ √ √ √ √ √ N/A √ √ √ 
Hoeven [25] √ √ √ √ √ √ √ √ √ √ 
Inoue [34] √ √ √ √ √ √ N/A √ X √ 
Jonsson [22] √ √ √ X √ √ N/A √ √ √ 
Meek [28] √ √ √ √ √ √ N/A √ √ √ 
Nielen [29] √ √ √ √ √ √ N/A √ √ √ 
Ong [30] √ √ √ √ √ √ N/A √ √ √ 
Rahman [24] √ √ √ √ √ √ √ √ √ √ 
Rahman [31] √ √ √ √ √ √ N/A √ √ √ 
Reid [23] √ √ √ √ X √ N/A √ X √ 
Singh [35] √ √ √ √ √ √ N/A √ √ √ 
Tsuboi [26] √ √ √ √ √ √ √ √ X √ 
Walston [27] √ √ √ √ √ √ √ √ √ √ 
 
√ - satisfied; X – not satisfied; N/A – not applicable 
Critical Appraisal Criteria 
1. Did the study address a clearly focused issue? 
2. Was the cohort recruited in an acceptable ways? 
3. Was the exposure accurately measured to minimise bias? 
4. Was the outcome accurately measured to minimise bias? 
5. Have the authors identified all important confounding factors? 
6. Was the follow-up of the subjects complete enough? 
7. Was the follow-up of subjects long enough? 
8. Were confidence intervals presented? 
9. Were the results generalisable to the general population? 
10. Do the results of the study fit with other available evidence? 
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Supplementary Table 3: Characteristics of included studies 
 
Study 
(Country) 
OA Joints N 
(Cases/Control) 
Gender (M/F) Mean Age 
(Case/Control) 
Study details Assessment of CVD 
Dahaghin [32] 
Netherlands 
Multiple 
joints 
3585 (N/S) 1499/2086 Total: 66.6/67.2 Community sample in Rotterdam. OA and 
Non-OA groups from same cohort. 
CV risk factors 
Han [17] Korea Knee 2234 (270/1964) 1020/1214 64.4/53.2 Korean National Health and Nutrition 
Examination Survey. OA and Non-OA 
groups from same cohort. 
Metabolic syndrome. By Hx, 
Ex, Ix 
Haugen [33] USA Hand 1348 (726/622) 623/725 Total: 62.8 Framingham Heart Study (Original and 
Offspring cohorts). Subjects community-
based and aged 50–75 years.  OA and 
Non-OA groups from same cohort. 
MI, CVA, HF, IHD, HTN, CV 
mortality 
Hoeven [25] 
Netherlands 
Knee, hip, 
hands 
5650 (N/S) 2372/3278 Total: 68.2 Rotterdam Study: community-based 
prospective population cohort study of 
the middle aged and elderly. OA and Non-
OA groups from same cohort. 
HTN, atherosclerosis (by USS 
carotids) 
Inoue [34] Japan Knee 795 (260/535) 290/500 M: 67.8; 
F:65.9/M:56.3; 
F:54.9 
Community-based sample. OA and Non-
OA groups from same cohort. 
Metabolic syndrome. By Hx, 
Ex, Ix 
Jonsson [22] 
Iceland 
Hand 5764 (N/S) 2264/3078 Total: 76.0 AGES Reykjavik Study: population-based 
ageing study. OA and Non-OA groups 
from same cohort. 
MI, CVA, IHD, HTN, 
atherosclerosis (by USS: 
carotid intima media 
thickness & carotid plaques; 
CT: calcification of coronary 
arteries & thoracic aorta) 
Meek [28] 
Netherlands 
Multiple 
joints 
5756 (1233 (168 
OA)/4523) 
2614/3142 (OA: 
37/131) 
N/S Two databases assessing CV risk factors 
from same region in Netherlands. OA 
cohort seen in clinic and screened for 
CVD; compared to Doetinchem 
population-based study (controls)  
Observed CV risk factors. By 
Hx, Ex, Ix 
Nielen [29] 
Netherlands 
Multiple 
joints 
175,956 (17,517 
(4040 
OA)/158,439) 
87,147/89,808 
(OA:1264/2276) 
65.3 (OA:69.8)/51 Netherlands Information Network of GPs. 
Nationally representative sample. OA 
and Non-OA groups from same cohort. 
MI, TIA, CVA, HTN 
Ong [30] USA Multiple 
joints 
15,295 
(5421/9874) 
7179/8116 
(OA:611/1263) 
62.3 
(OA:63.9)/54.3 
NHANES 1999-2008 nationally-
representative database.  OA and Non-OA 
groups from same cohort. 
MI, CVA, HF, IHD 
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Rahman [24] 
Canada 
N/S  49,631 
12,745/36,886 
20,221/29,410 58.2/57.5 Random sample from Canadian health 
database. Patients tracked until they 
received diagnosis for CVD during the 
study period. 
MI, CVA, HF, IHD 
Rahman [31] 
Canada 
N/S 81,634 
(40,817/40,817) 
23,184/58,450 66/66 Random sample from Canadian health 
database. Patients tracked until they 
received diagnosis for CVD during the 
study period. 
MI, CVA, HF, IHD 
Reid [23] USA N/S 6299 (N/S) 2835/3464 Total: 
M:51.7/F:51.7 
Native American database surveillance. 
Both groups recruited and data collected 
from visits to hospital clinic.  
Observed CV risk factors. By 
Hx, Ex, Ix, assessing Dx and Rx 
lists 
Singh [35] USA Multiple 
joints 
30,060,457 (OA: 
24,345,370) 
10,765,031/19,2
95,426 (OA: 
9,015,680/15,32
9,690) 
N/S Third National Health and Nutrition 
Examination Survey.  OA and Non-OA 
groups from same cohort.   
IHD, CVA and association with 
HTN 
Tsuboi [26] 
Japan 
Hand 789 (244/545) 329/460 68.5/57.6 Cohort study in a rural Japanese 
community.  OA and Non-OA groups 
from same cohort. 
CV mortality 
Walston [27] UK Multiple 
joints 
2,373,551 
(175,207) 
(163,574 
OA/2,198,344) 
1,109,574/1,263,
977 (OA: 
61,517/101,757) 
Total M:54.5/57.2 UK GP research database. OA and Non-
OA groups from same cohort. 
MI, CVA, CV mortality 
 
BMI – body mass index; BP - blood pressure; CV – cardiovascular; CVA – cerebrovascular accident; CT – computed tomography; DM – diabetes 
mellitus; Ex – examination; F – Females; HbA1c - glycosylated haemoglobin; hsCRP – high-sensitivity C-reactive protein ; HF – heart failure; HOMA-
IR: homeostasis model assessment of insulin resistance index; HTN – hypertension; Hx - history; IHD – ischemic heart disease; HDL - high-density 
lipoprotein; Ix – laboratory investigations; LDL - low-density lipoprotein; M – Males; MI – myocardial infarct; N – Numbers; N/S – Not stated; NSAID - 
non-steroidal anti-inflammatory; N – Numbers; N/S – Not stated; OA- osteoarthritis; Rx – treatment; SES - socioeconomic status; TC - total 
cholesterol; TIA – transient ischemic attack; TG - triglycerides; UK – United Kingdom; USA – United States of America; USS – ultrasound scan; WC – 
waist circumference  
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Supplementary Table 4: Cardiovascular disease risk factors and assessment of CVD in the included studies. 
 
Study CV Risk Factor OA - Male  OA - Female OA - Total Non-OA - 
Male 
Non-OA - Female Non-OA - Total 
Dahaghin [32] DM (%) {OR [95% CI]}             
 Age 55-62 - - 22.8 {1.2 [0.9-1.6]} - - 14.2 
  Age 62.1-68.7 - - 28.9 {1.1 [0.7-1.8]} - - 27 
   Age >68.8 - - 41.5 {0.9 [0.6-1.4]} - - 42.5 
  Total - - 32  {1.2 [0.9-1.6]} - - 27.1 
Han [17] Fasting blood glucose (mg/dl [SD]) 99.5 [17.0] 100.0 [18.1] 99.9 [17.9] 100.2 [18.6] 98.3 [17.7] 99.2 [18.2] 
 Weight (kg) 65.9 [10.5] 57.3 [8.9] 58.3 [9.5] 66.6 [9.6] 57.5 [8.5] 62.0 [10.1] 
  BMI (kg/m2) 23.4 [3.6] 24.8 [3.2] 24.6 [3.3] 23.7 [2.9] 23.9 [3.2] 23.8 [3.1] 
  Current smoker (%) 46.3 9.2 14.8 54.6 5.6 30 
  Ex-smoker (%) 41.5 1.7 7.8 23.9 0.9 12.4 
  Alcohol consumption (%) 85.4 43.2 49.6 83.4 4.6 66.4 
  Exercise (%) 31.7 19.7 21.6 34.7 25.8 30.2 
  HDL cholesterol (mg/dl) [range] 153.9 [80.5] 45.5 [9.8] 45.0 [10.2] 163.4 [84.4] 47.5 [10.2] 45.5 [10.3] 
  Systolic BP (mmHg) [range] 132.8 [20.5] 133.3 [21.0] 133.2 [20.9] 128.7 [19.3] 124.0 [20.7] 126.4 [20.2] 
Haugen [33] High blood glucose (%) - - 7.7; 9.1 - - 6.1 
 BMI (kg/m2) [SD] - - 28.0 [4.4]; 27.8[4.9] - - 27.4 [4.5] 
 TC:HDL ratio [SD] - - 4.5 [1.4]; 4.5 [1.4] - - 4.6 [1.6] 
 Hypertension (%) - - 10.2; 8.9 - - 5 
 Anti-HTN meds. (%) - - 38.3; 33.3 - - 19.8 
 Lipid-lowereing meds. (%) - - 14.5; 9.8 - - 9.5 
 NSAID meds.(%) - - 18.8; 11.5 - - 10.6 
 Anti-diabetic meds. (%) - - 5.9; 4.6 - - 2.6 
 Daily aspirin use (%) - - 24.5; 23.6 - - 14.1 
 Alcohol consumption (%) - - 64; 63.5 - - 68.4 
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 Smoking (%) - - 37.6; 40.6 - - 50.8 
  Inactivity (%) - - 36.8; 35.1 - - 30.7 
Hoeven [25] None Documented - - - - - - 
Inoue [34] Diabetes mellitus (%) 4 9 13 19 3 22 
 HbA1c (%) [range] 5.3 [0.5] 5.3 [0.8] - 5.3 [0.7] 5.1 [0.3] - 
  BMI (kg/m2) [range] 23.6 [2.8] 23.8 [3.6] - 23.5 [2.7] 22.3 [2.7 - 
  Waist circumference (cm) [range] 84.5 [7.9] 85.2 [9.6] - 84.6 [7.4] 80.5 [8.2] - 
  Smoking (%) 19.2 2.4 - 33.7 11.6 - 
  Alcohol consumption (%) 80.8 12.5 - 73.7 25.7 - 
  Exercise (%) 19.2 32.2 - 30 26 - 
  HDL cholesterol (mg/dl) [range] 59.7 [17.6] 62.2 [14.9] - 55.9 [15.2] 64.2 [14.2] - 
  Triglyceride (mg/dl) [range] 80.9 [40.4] 90.1 [44.6] - 134.4 [119.0] 80.8 [41.0] - 
  Hyperlipidaemia (%) 11.5 22.1 - 9.1 8.6 - 
  Systolic BP (mmHg) [range] 137.6 [18.4] 130.7 [18.6] - 128.9 120 - 
  Hypertension (%) 23.1 15.4 - 23.5 17.8 - 
  Metabolic syndrome (%) 23.1 15.4 - 22.2 5.1 - 
Jonsson [22] None Documented - - - - - - 
Meek [28] BMI (kg/m2) - - 29.1 - - 26.6 
 BMI >25 (%) - - 80.5 - - 61.9 
  BMI >30 (%) - - 34 - - 17.3 
  Total cholesterol (mmol/l) - - 5.53 - - 5.58 
  Total cholesterol >6.5 mmol/l (%) - - 15.9 - - 16.3 
  HDL cholesterol (mmol/l) - - 1.47 - - 1.43 
  HDL cholesterol <0.9 mmol/l (%) - - 8.1 - - 8.2 
  TC:HDL ratio - - 4 - - 4.2 
  Lipid-lowering medication use (%) - - 13.1 - - 10.1 
  Abnormal lipid profile incl. med - - 35.5 - - 31.5 
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(%) 
  Ever smoker (%) - - 61.1 - - 62.7 
  Current smoker (%) - - 20.6 - - 20.5 
  Systolic BP (mmHg) [range] - - 146.7 - - 135.7 
  BP >140/90 or anti-HTN use (%) - - 68.1 - - 56 
Nielen [29] Diabetes mellitus (%) - - 16.5 - - - 
 Hypercholesterolaemia (%) - - 13.3 - - 4.8 
  Hypertension (%) - - 38.5 - - 13.3 
Ong [30] HbA1c (%) [range] - - 5.61 [5.56-5.65] - - 5.49 [5.46-5.52] 
 Fasting blood glucose (mmol/L) 
[range] 
- - 5.90 [5.80-6.00] - -  5.83 [5.78-5.87] 
  Fasting insulin (mU/L) [range] - - 7.74 [7.19-8.33] - - 7.21 [6.91-7.53] 
  HOMA-IR* [range] - - 2.03 [1.88-2.20] - - 1.87 [1.78-1.96] 
  HbA1c multiple regression analysis - - 0.38 [0.08-1.31] - - - 
  BMI (kg/m2) - - 29.7 - - 28.2 
  HDL cholesterol (mmol/l) - - 1.43 - - 1.38 
  LDL cholesterol (mmol/l) - - 3.11 - - 3.22 
  Triglyceride (mmol/l) [range] - - 1.52 [1.45-1.60] - - 1.42 [1.38-1.45] 
  Total cholesterol (mmol/l) - - 5.37 - - 5.38 
  Lipid-lowering meds.(%) - - 28.7 - - 16.1 
  Systolic BP (mmHg) - - 131.3 - - 126 
  Hypertension (%) - - 58.9 - - 37.5 
  Current smoker (%) - - 14.1 - - 20.9 
  Ex-smoker (%) - - 39.3 - - 29.4 
  Alcohol consumption (%) - - 26.4 - - 35 
Rahman [24] Diabetes mellitus (RR)[95% CI]{%}             
 Age <65 2.05 [1.70-1.22] 2.30 [1.89-2.80] 1.73 [1.60-1.88]{5.2} - - {4.7} 
  Age >65 1.50 [1.29-1.74] 1.79 [1.56-2.05] - - - - 
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  Hyperlipidaemia (%) - - 6 - - 4.9 
  BMI 25-29.9 (%) - - 32.1 - - 36.7 
  BMI >30 (%) - - 34.4 - - 17.7 
  Hypertension (%) - - 19.7 - - 16.4 
Rahman [31] BMI >30 (OR)[95% CI]{%} 1.23 [1.04-1.45] 1.09 [0.96-1.23] 1.14 [1.03-1.26]{11.5} - - 9.9 
 BMI 25-29.9 (OR)[95% CI]{%} 1.09 [0.95-1.24] 0.94 [0.84-1.04] 0.99 [0.92-1.08]{32.1} - - 29.7 
  Current smoker (OR)[95% CI]{%} 1.40 [1.16-1.69] 1.09 [0.96-1.25] 1.16 [1.04-1.29){19.7} - - 19 
  Ex-smoker (OR)[95% CI]{%} 1.39 [1.20-1.61] 1.16 [1.06-1.26] 1.19 [1.11-1.29]{49.6} - - 46.6 
  Inactivity (OR)[95% CI]{%} 1.28 [1.11-1.48] 1.37 [1.20-1.26] 1.33 [1.21-1.47]{60.6] - - 58.5 
  Diabetes mellitus (OR)[95% CI]{%} 1.80 [1.57-2.06] 1.96 [1.76-2.19] 1.90 [1.75-2.01]{11.5} - - 9.9 
  Hypertension (OR)[95% CI]{%} 1.92 [1.72-2.14] 2.01 [1.84-2.18] 1.98 [1.86-2.12]{36.7} - - 32.1 
Reid [23] DM (OR)[95% CI]             
 Age 35-44 1.36 [0.66-2.80] 1.90 [1.06-3.40]   - - - 
  Age 45-54 1.04 [0.62-1.74] 1.62 [1.09-2.42]   - - - 
  Age 55-64 0.60 [0.35-1.01] 1.31 [0.87-1.99]   - - - 
  Age >65 1.63 [1.00-2.67 1.25 [0.80-1.94]   - - - 
  Hypertension (OR)[95% CI]          
  Age 35-44 4.07 [1.94-8.51] 2.65 [1.54-4.54]   - - - 
  Age 45-54 5.35 [2.81-
10.17] 
5.40 [3.36-8.66]   - - - 
  Age 55-64 8.79 [3.98-
19.38] 
4.24 [2.50-7.21]   - - - 
  Age >65 12.63 [5.25-
30.37] 
8.46 [4.81-14.90]   - - - 
  BMI 25.0-29.9 (OR)[95% CI]          
  Age 35-44 0.93 [0.18-4.82] 1.36 [0.58-3.19]   - - - 
  Age 45-54 2.79 [0.80-9.78] 1.14 [0.52-2.51]   - - - 
  Age 55-64 1.26 [0.37-4.24] 1.45 [0.65-3.26]   - - - 
  Age >65 1.21 [0.58-2.54] 0.86 [0.47-1.57]   - - - 
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  BMI 30-34.9 (OR)[95% CI]          
  Age 35-44 1.38 [0.29-6.51] 0.99 [ 0.40-2.44]   - - - 
  Age 45-54 2.12 [0.60-7.51] 1.56 [0.74-3.28]   - - - 
  Age 55-64 2.05 [0.63-6.72] 2.01 [0.90-4.46]   - - - 
  Age >65 1.03 [0.47-2.25] 0.95 [0.52-1.73]   - - - 
  BMI 35-39.9  (OR)[95% CI]{%}          
  Age 35-44 1.02 [0.2-5.37] 0.82 [0.31-2.13]   - - - 
  Age 45-54 2.88 [0.78-
10.61] 
2.00 [0.94-4.26]   - - - 
  Age 55-64 2.51 [0.73-8.66] 3.88 [1.73-8.70]   - - - 
  Age >65 1.35 [0.54-3.39] 0.43 [0.20-0.93]   - - - 
  BMI >40  (OR)[95% CI]{%}          
  Age 35-44 2.95 [0.60-
14.53] 
2.01 [0.86-4.68]   - - - 
  Age 45-54 3.31 [0.91-
12.03] 
2.40 [1.12-5.14]   - - - 
  Age 55-64 3.94 [1.07-
14.51] 
3.09 [1.38-6.94]   - - - 
  Age >65 1.06 [0.38-2.97] 1.33 [0.60-2.94]   - - - 
  Current Smoker (OR)[95% CI]          
  Age 35-44 1.96 [1.03-3.74] 1.75 [1.04-2.97]   - - - 
  Age 45-54 1.30 [0.76-2.21] 1.52 [1.01-2.30]   - - - 
  Age 55-64 2.05 [1.20-3.52] 2.15 [1.34-3.47]   - - - 
  Age >65 2.99 [1.52-5.89] 1.25 [0.63-2.47]   - - - 
Singh [35] None Documented - - - - - - 
Tsuboi [26] BMI (kg/m2) [range] - - 24.8 [3.2] - - 23.6 [3.0] 
 Smoking (%) - - 21.3 - - 31 
  Alcohol consumption (%) - - 18 - - 27 
  Exercise (%) - - 22.5 - - 24 
Walston [27] None Documented - - - - - - 
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BMI – body mass index; BP - blood pressure; CV – cardiovascular; CVA – cerebrovascular accident; CT – computed tomography; DM – diabetes 
mellitus; Ex – examination; HbA1c - glycosylated haemoglobin; hsCRP – high-sensitivity C-reactive protein ; HF – heart failure; HOMA-IR: 
homeostasis model assessment of insulin resistance index; HTN – hypertension; Hx - history; IHD – ischemic heart disease; HDL - high-density 
lipoprotein; Ix – laboratory investigations; LDL - low-density lipoprotein; MI – myocardial infarct; NSAID - non-steroidal anti-inflammatory; N – 
Numbers; N/S – Not stated; Rx – treatment; SES - socioeconomic status; TC - total cholesterol; TIA – transient ischemic attack; TG - triglycerides; WC – 
waist circumference; USS – ultrasound scan. 
